 ATR inhibition reverses the resistance of homologous recombination-deficient MGMT-LO slash MMR-proficient cancer cells to temozolamide. Temozolamide, or TMZ, is a DNA-alglating agent currently approved to treat glioblastoma and advanced melanoma. TMZ can induce DNA damage, eliciting many responses in a variety of cancer cells, including cell death, autophagy, and senescence. However, therapeutic efficacy of TMZ is hindered by inherent and acquired resistance. In the cover paper chosen for Oncotarget's Volume 12, Issue 21, researchers investigated biomarkers of TMZ resistance and sensitivity. Read about this study in more peer-reviewed oncology-focused research published by Oncotarget at oncotarget.com.